サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：バイオベターの世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）
市場調査レポート
商品コード
1420306

バイオベターの世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）

Biobetters Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
出版日: | 発行: Fairfield Market Research | ページ情報: 英文 242 Pages | 納期: 2～5営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
バイオベターの世界市場 - 世界の業界分析、規模、シェア、成長、動向、予測（2031年）
出版日: 2024年01月18日
発行: Fairfield Market Research
ページ情報: 英文 242 Pages
納期: 2～5営業日
  • 全表示
  • 概要
  • 目次
概要

世界のバイオベターの市場規模は、2024年から2031年にかけて力強い成長を示しています。この成長軌道は今後も続き、2024年から2031年にかけてのCAGRは10%と予想されています。2024年、バイオベターの世界市場規模は600億米ドルに達し、2031年には1,150億米ドルに達すると予測されています。

バイオベターはバイオスーペリアとも呼ばれ、既存のバイオ医薬品と同じカテゴリーに属する組み換えタンパク質医薬品の一種です。バイオベターは、既存のバイオ医薬品と同じカテゴリーに属するが、原薬と同一ではないという点で異なります。バイオベターは、臨床効果を高め、忍容性を改善し、投与回数を減らし、副作用を軽減するように設計されています。優れた治療効果、副作用の軽減、費用対効果の高い製造方法、非特許および市場独占性、製品半減期の延長、投与回数の削減、魅力的な投資機会など、バイオベターには数多くの利点があるため、バイオベター市場は成長する見込みです。

バイオベターは既存の生物学的製剤を改良したもので、治療効果の向上、副作用の軽減、投与回数の減少を実現します。この優れた有効性と投与回数の少なさは患者のコンプライアンスに貢献し、市場の大幅な成長を牽引すると期待されています。

バイオベターは、ペグ化やアルブミン置換などの最新技術を取り入れた生物製剤と同様の工程で製造されます。これらの技術によってバイオベターの製造は合理化され、生物学的製剤に比べてコスト効率が高くなっています。生物製剤の開発期間が約15年と長いのに対し、バイオベターの開発期間は約10年と短いです。バイオシミラーの開発コストはバイオベターの約半分であるが、治療効果はバイオベターの方が優れています。

バイオ医薬品メーカーや投資家による改良型製剤開発のための継続的な研究活動が、バイオベター市場の拡大を後押ししています。先進的な生物物理学的・生化学的アプローチが登場し、業界の成長に大きな勢いをもたらしています。

当レポートでは、世界のバイオベター市場について調査し、市場の概要とともに、製品タイプ別、適応症別、投与経路別、流通チャネル別、地域別動向、および市場に参入する企業の競合動向などを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場の定義とセグメンテーション
  • 市場力学
  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19の影響分析
  • ウクライナとロシアの紛争の影響
  • 経済概要
  • PESTLE分析

第3章 世界のバイオベターズ市場の見通し、2018年～2031年

  • 世界のバイオベターズ市場の見通し、製品タイプ別、金額（10億米ドル）、2018年～2031年
  • 世界のバイオベターズ市場の見通し、適応症別、金額（10億米ドル）、2018年～2031年
  • 世界のバイオベターズ市場の見通し、投与経路別、金額（10億米ドル）、2018年～2031年
  • 世界のバイオベターズ市場の見通し、流通チャネル別、金額（10億米ドル）、2018年～2031年
  • 世界のバイオベターズ市場の見通し、地域別、金額（10億米ドル）、2018年～2031年

第4章 北米のバイオベターズ市場の見通し、2018年～2031年

第5章 欧州のバイオベターズ市場の展望、2018年～2031年

第6章 アジア太平洋のバイオベターズ市場の展望、2018年～2031年

第7章 ラテンアメリカのバイオベターズ市場の見通し、2018年～2031年

第8章 中東・アフリカのバイオベターズ市場の見通し、2018年～2031年

第9章 競合情勢

  • 製品と適応症のヒートマップ
  • 企業の市場シェア分析、2023年
  • 競合ダッシュボード
  • 企業プロファイル
    • F.Hoffmann-La Roche AG
    • Merck & Co. Inc.
    • Sanofi SA
    • SERVIER
    • Porton Biopharma Limited
    • Eli Lily and Company
    • Novo Nordisk A/S
    • Biogen Inc.
    • CSL Behring GmbH
    • Teva Pharmaceutical Industries Ltd.

第10章 付録

目次

The global Biobetters Market has demonstrated robust growth from 2024 to 2031. This growth trajectory is set to continue, with an anticipated steady CAGR of 10% expected between 2024 and 2031. In 2024, the global Biobetters Market reached a size of US$ 60 billion, and it is projected to attain a valuation of US$ 115 billion by 2031.

Overview of the Biobetters Market

Biobetters, also known as biosuperiors, represent a class of recombinant protein drugs that belong to the same category as existing biopharmaceuticals. However, they are distinct in that they are not identical to the source drugs. Biobetters are designed to enhance clinical efficacy, improve tolerance, reduce dosing frequency, and lower side effects. The Biobetters Market is poised to grow due to their numerous advantages, including superior therapeutic efficacy, reduced side effects, cost-effective production methods, non-patent and market exclusivity, extended product half-life, reduced dosage frequency, and attractive investment opportunities.

Factors Driving the Growth of the Biobetters Market

"High Efficacy and Few Side Effects"

Biobetters are engineered to be improved versions of existing biologics, offering enhanced therapeutic benefits, reduced side effects, and less frequent dosing. This superior efficacy and lower dosing frequency contribute to patient compliance and are expected to drive significant market growth.

"Simple and Cost-effective Manufacturing Process"

Biobetters are manufactured using processes similar to biologics, with the incorporation of modern technologies such as pegylation and albumin replacement. These techniques have streamlined the production of biobetters, making it more cost-effective compared to biologics. Biobetters have a shorter development timeline, approximately 10 years, in contrast to the longer development period of around 15 years for biologics. While biosimilars require roughly half the development cost of biobetters, the latter offer superior therapeutic effectiveness.

"Increasing Research Activities"

Continuous research efforts by biopharmaceutical manufacturers and investors to develop improved formulations are driving the expansion of the biobetters market. Advanced biophysical and biochemical approaches have emerged, providing significant momentum to the industry's growth.

"Increased Investment in Developing Therapeutic Agents"

The growing investment in developing therapeutic agents with enhanced effectiveness and safety profiles for conditions such as cancers and autoimmune diseases is influencing the biobetters market positively. Efforts to mitigate the economic impact of chronic diseases have led to substantial investments in new drug development, further fueling market growth.

Challenges Faced by the Biobetters Market

"High Investments Required for R&D Activities"

The development of novel medicinal drugs, including biobetters, demands substantial investments in research and development, which can act as a limitation on market growth. However, the post-COVID-19 era has witnessed a significant surge in R&D spending for the development of biobetters. Additionally, increasing biosimilar competition poses challenges to market expansion.

Impact of COVID-19 on the Biobetters Market

"Increase in Investment for Developing Novel Biobetters"

The COVID-19 pandemic has prompted a notable increase in R&D investment for the development of novel biobetters. Manufacturers and investors in the biobetter industry are actively working on improving formulations, resulting in numerous novel medications in the pipeline or undergoing clinical trials.

Competitive Landscape

The Biobetters market is characterized by intense competition, with several major players dominating the industry. Market participants are focusing on mergers and strategic alliances to expand their product portfolios and enhance market share, leveraging the industry's growth phase.

Key Companies Profiled

  • F.Hoffmann-La Roche AG
  • Merck & Co. Inc.
  • Sanofi SA
  • SERVIER
  • Porton Biopharma Limited
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Biogen Inc.
  • CSL Behring GmbH
  • Teva Pharmaceutical Industries Ltd.

Biobetters Market Segmentation

Biobetters Market by By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Biobetters Market By Molecule Type

  • G-CSF Biobetters
  • Insulin Biobetters
  • Erythropoietin Biobetters
  • Monoclonal Antibodies Biobetters
  • Others

Biobetters Market by Disease Indication

  • Cancer
  • Diabetes
  • Genetic disease
  • Neurological Disorders
  • Others

Biobetters Market by Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

  • 1.1. Global Biobetters Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Biobetters Market Outlook, 2018 - 2031

  • 3.1. Global Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Erythropoietin Biobetters
      • 3.1.1.2. G-CSF Biobetters
      • 3.1.1.3. Interferon Biobetters
      • 3.1.1.4. Insulin Biobetters
      • 3.1.1.5. Monoclonal Antibodies Biobetters
      • 3.1.1.6. Anti-haemophilic Factor
      • 3.1.1.7. Others
  • 3.2. Global Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Diabetes
      • 3.2.1.2. Cancer
      • 3.2.1.3. Renal Disease
      • 3.2.1.4. Neurodegenerative Disease
      • 3.2.1.5. Genetic Disorders (Haemophilia)
      • 3.2.1.6. Others
  • 3.3. Global Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Subcutaneous
      • 3.3.1.2. Intravenous
  • 3.4. Global Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospital Pharmacies
      • 3.4.1.2. Retail Pharmacies
      • 3.4.1.3. Online Pharmacies
  • 3.5. Global Biobetters Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Biobetters Market Outlook, 2018 - 2031

  • 4.1. North America Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Erythropoietin Biobetters
      • 4.1.1.2. G-CSF Biobetters
      • 4.1.1.3. Interferon Biobetters
      • 4.1.1.4. Insulin Biobetters
      • 4.1.1.5. Monoclonal Antibodies Biobetters
      • 4.1.1.6. Anti-haemophilic Factor
      • 4.1.1.7. Others
  • 4.2. North America Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Diabetes
      • 4.2.1.2. Cancer
      • 4.2.1.3. Renal Disease
      • 4.2.1.4. Neurodegenerative Disease
      • 4.2.1.5. Genetic Disorders (Haemophilia)
      • 4.2.1.6. Others
  • 4.3. North America Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Subcutaneous
      • 4.3.1.2. Intravenous
  • 4.4. North America Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies
      • 4.4.1.2. Retail Pharmacies
      • 4.4.1.3. Online Pharmacies
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis
  • 4.5. North America Biobetters Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 4.5.1.2. U.S. Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.5.1.3. U.S. Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 4.5.1.4. U.S. Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.5.1.5. Canada Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 4.5.1.6. Canada Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 4.5.1.7. Canada Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 4.5.1.8. Canada Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Biobetters Market Outlook, 2018 - 2031

  • 5.1. Europe Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Erythropoietin Biobetters
      • 5.1.1.2. G-CSF Biobetters
      • 5.1.1.3. Interferon Biobetters
      • 5.1.1.4. Insulin Biobetters
      • 5.1.1.5. Monoclonal Antibodies Biobetters
      • 5.1.1.6. Anti-haemophilic Factor
      • 5.1.1.7. Others
  • 5.2. Europe Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Diabetes
      • 5.2.1.2. Cancer
      • 5.2.1.3. Renal Disease
      • 5.2.1.4. Neurodegenerative Disease
      • 5.2.1.5. Genetic Disorders (Haemophilia)
      • 5.2.1.6. Others
  • 5.3. Europe Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Subcutaneous
      • 5.3.1.2. Intravenous
  • 5.4. Europe Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Retail Pharmacies
      • 5.4.1.3. Online Pharmacies
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis
  • 5.5. Europe Biobetters Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.2. Germany Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.3. Germany Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.4. Germany Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.5. U.K. Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.6. U.K. Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.7. U.K. Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.8. U.K. Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.9. France Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.10. France Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.11. France Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.12. France Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.13. Italy Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.14. Italy Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.15. Italy Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.16. Italy Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.17. Turkey Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.18. Turkey Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.19. Turkey Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.20. Turkey Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.21. Russia Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.22. Russia Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.23. Russia Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.24. Russia Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.5.1.25. Rest of Europe Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 5.5.1.26. Rest of Europe Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 5.5.1.27. Rest of Europe Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.5.1.28. Rest of Europe Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Biobetters Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Erythropoietin Biobetters
      • 6.1.1.2. G-CSF Biobetters
      • 6.1.1.3. Interferon Biobetters
      • 6.1.1.4. Insulin Biobetters
      • 6.1.1.5. Monoclonal Antibodies Biobetters
      • 6.1.1.6. Anti-haemophilic Factor
      • 6.1.1.7. Others
  • 6.2. Asia Pacific Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Diabetes
      • 6.2.1.2. Cancer
      • 6.2.1.3. Renal Disease
      • 6.2.1.4. Neurodegenerative Disease
      • 6.2.1.5. Genetic Disorders (Haemophilia)
      • 6.2.1.6. Others
  • 6.3. Asia Pacific Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Subcutaneous
      • 6.3.1.2. Intravenous
  • 6.4. Asia Pacific Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Retail Pharmacies
      • 6.4.1.3. Online Pharmacies
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis
  • 6.5. Asia Pacific Biobetters Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.2. China Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.3. China Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.4. China Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.5. Japan Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.6. Japan Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.7. Japan Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.8. Japan Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.9. South Korea Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.10. South Korea Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.11. South Korea Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.12. South Korea Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.13. India Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.14. India Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.15. India Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.16. India Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.17. Southeast Asia Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.18. Southeast Asia Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.19. Southeast Asia Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.20. Southeast Asia Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Biobetters Market Outlook, 2018 - 2031

  • 7.1. Latin America Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Erythropoietin Biobetters
      • 7.1.1.2. G-CSF Biobetters
      • 7.1.1.3. Interferon Biobetters
      • 7.1.1.4. Insulin Biobetters
      • 7.1.1.5. Monoclonal Antibodies Biobetters
      • 7.1.1.6. Anti-haemophilic Factor
      • 7.1.1.7. Others
  • 7.2. Latin America Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Diabetes
      • 7.2.1.2. Cancer
      • 7.2.1.3. Renal Disease
      • 7.2.1.4. Neurodegenerative Disease
      • 7.2.1.5. Genetic Disorders (Haemophilia)
      • 7.2.1.6. Others
  • 7.3. Latin America Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Subcutaneous
      • 7.3.1.2. Intravenous
  • 7.4. Latin America Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Retail Pharmacies
      • 7.4.1.3. Online Pharmacies
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis
  • 7.5. Latin America Biobetters Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Brazil Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.2. Brazil Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.3. Brazil Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.4. Brazil Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.5.1.5. Mexico Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.6. Mexico Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.7. Mexico Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.8. Mexico Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.5.1.9. Argentina Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.10. Argentina Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.11. Argentina Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.12. Argentina Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.5.1.13. Rest of Latin America Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 7.5.1.14. Rest of Latin America Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 7.5.1.15. Rest of Latin America Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.5.1.16. Rest of Latin America Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Biobetters Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Biobetters Market Outlook, by Product Type, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Erythropoietin Biobetters
      • 8.1.1.2. G-CSF Biobetters
      • 8.1.1.3. Interferon Biobetters
      • 8.1.1.4. Insulin Biobetters
      • 8.1.1.5. Monoclonal Antibodies Biobetters
      • 8.1.1.6. Anti-haemophilic Factor
      • 8.1.1.7. Others
  • 8.2. Middle East & Africa Biobetters Market Outlook, by Indication, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Diabetes
      • 8.2.1.2. Cancer
      • 8.2.1.3. Renal Disease
      • 8.2.1.4. Neurodegenerative Disease
      • 8.2.1.5. Genetic Disorders (Haemophilia)
      • 8.2.1.6. Others
  • 8.3. Middle East & Africa Biobetters Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Subcutaneous
      • 8.3.1.2. Intravenous
  • 8.4. Middle East & Africa Biobetters Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Retail Pharmacies
      • 8.4.1.3. Online Pharmacies
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis
  • 8.5. Middle East & Africa Biobetters Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.2. GCC Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.3. GCC Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.4. GCC Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.5. South Africa Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.6. South Africa Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.7. South Africa Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.8. South Africa Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.9. Egypt Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.10. Egypt Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.11. Egypt Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.12. Egypt Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.13. Nigeria Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.14. Nigeria Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.15. Nigeria Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.16. Nigeria Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Biobetters Market by Product Type, Value (US$ Bn), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Biobetters Market by Indication, Value (US$ Bn), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Biobetters Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Biobetters Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Product vs Indication Heatmap
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. F.Hoffmann-La Roche AG
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Merck & Co. Inc.
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Sanofi SA
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. SERVIER
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Porton Biopharma Limited
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Eli Lily and Company
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Novo Nordisk A/S
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Biogen Inc.
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. CSL Behring GmbH
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Teva Pharmaceutical Industries Ltd.
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations